ZA200509169B - Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor - Google Patents

Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor

Info

Publication number
ZA200509169B
ZA200509169B ZA200509169A ZA200509169A ZA200509169B ZA 200509169 B ZA200509169 B ZA 200509169B ZA 200509169 A ZA200509169 A ZA 200509169A ZA 200509169 A ZA200509169 A ZA 200509169A ZA 200509169 B ZA200509169 B ZA 200509169B
Authority
ZA
South Africa
Prior art keywords
subunit
selectivity
alpha
treating
compounds
Prior art date
Application number
ZA200509169A
Other languages
English (en)
Inventor
Barbara Langen
Chris Rundfelst
Rita Dost
Hartmut Lueddens
Holger Rabe
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of ZA200509169B publication Critical patent/ZA200509169B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200509169A 2003-07-11 2005-11-14 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor ZA200509169B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48667803P 2003-07-11 2003-07-11

Publications (1)

Publication Number Publication Date
ZA200509169B true ZA200509169B (en) 2006-07-26

Family

ID=34062138

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200509169A ZA200509169B (en) 2003-07-11 2005-11-14 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor

Country Status (17)

Country Link
US (2) US20050032863A1 (xx)
EP (2) EP1646386A2 (xx)
JP (1) JP2009513539A (xx)
KR (1) KR20060032633A (xx)
CN (2) CN101254189A (xx)
AR (1) AR045013A1 (xx)
AU (1) AU2004255414A1 (xx)
BR (1) BRPI0412512A (xx)
CA (1) CA2531861A1 (xx)
MX (1) MXPA05013196A (xx)
NO (1) NO20060686L (xx)
NZ (1) NZ544251A (xx)
RU (1) RU2354377C2 (xx)
TW (1) TW200512197A (xx)
UA (1) UA87982C2 (xx)
WO (1) WO2005004867A2 (xx)
ZA (1) ZA200509169B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101802A1 (en) * 2006-03-08 2007-09-13 F. Hoffmann-La Roche Ag 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones
AU2010289281A1 (en) 2009-09-04 2012-04-12 Vanderbilt University mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
RU2014109074A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
CN104199105A (zh) * 2014-08-27 2014-12-10 中国石油天然气集团公司 高密度三维勘探中初至的拾取方法及拾取装置
CN109564229A (zh) * 2016-07-11 2019-04-02 兰维尔健康有限公司 基于味觉识别的诊断相关性的方法
CA3146837A1 (en) * 2019-08-06 2021-02-11 Ulf Simonsen Compound for combination treatment
KR102489109B1 (ko) * 2020-06-02 2023-01-16 부산대학교 산학협력단 아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90869C (fi) * 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
WO1997000931A1 (en) 1995-06-23 1997-01-09 Bausch & Lomb Incorporated Method for cleaning contact lenses utilizing polysulfonates
DE19532668A1 (de) * 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en) 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
WO1999037370A1 (en) 1998-01-22 1999-07-29 Precedence Publishing, Inc. Game using collectibles as playing pieces
GB9821179D0 (en) 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
GB0122696D0 (en) * 2001-09-20 2001-11-14 Merck Sharp & Dohme Therapeutic agents
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs

Also Published As

Publication number Publication date
CA2531861A1 (en) 2005-01-20
BRPI0412512A (pt) 2006-09-19
NZ544251A (en) 2009-12-24
RU2006104118A (ru) 2006-06-10
AU2004255414A1 (en) 2005-01-20
JP2009513539A (ja) 2009-04-02
TW200512197A (en) 2005-04-01
CN1822836A (zh) 2006-08-23
US20050032863A1 (en) 2005-02-10
NO20060686L (no) 2006-03-14
AR045013A1 (es) 2005-10-12
KR20060032633A (ko) 2006-04-17
MXPA05013196A (es) 2006-03-09
CN101254189A (zh) 2008-09-03
US20080114032A1 (en) 2008-05-15
RU2354377C2 (ru) 2009-05-10
WO2005004867A2 (en) 2005-01-20
EP1646386A2 (en) 2006-04-19
EP2027856A1 (en) 2009-02-25
UA87982C2 (ru) 2009-09-10
WO2005004867A3 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
EP1434801A4 (en) TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
AP2006003771A0 (en) Substituted morpholine compounds for the treatmentof central nervous system disorders
EP1471909A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
IL169091A0 (en) Benzazepine derivatives for the treatment of neurological disorders
ZA200509169B (en) Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
EP1755654A4 (en) METHODS AND SYSTEMS FOR TREATING NEUROLOGICAL DISEASES OF THE CENTRAL NERVOUS SYSTEM
PT1666462E (pt) Derivados de n-[1h-indol-5-il]-naftaleno-1-sulfonamida e compostos associados enquanto antagonistas do receptor 5- ht6 de serotonina para o tratamento de distúrbios do sistema nervoso central
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
IL148052A0 (en) Use of gaba antagonists for treatment of spastic disorders, convulsions, and epilepsy
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
IL170710A0 (en) Selective cytokine inhibitory drugs for treating disorders of the central nervous system
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
AU2003202255A8 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
AU2003269883A8 (en) Diagnostic markers for disorders of the nervous system
HK1040933A1 (zh) N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用
GB0010496D0 (en) Treatment of conditions of the central nervous system
HK1088317A1 (en) 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
HUP0303921A3 (en) Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops
AU2002339699A8 (en) Use of obg3 for promoting central nervous system remyelination